About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Acute Maternal Hyperoxygenation in CHD

Clinicaltrials.gov identifier NCT03944837

Recruitment Status Recruiting

First Posted May 10, 2019

Last update posted August 12, 2020

Study Description

Brief summary:

Congenital heart disease (CHD) is predominantly detected before birth. Using echocardiography and MRI, this study will determine whether acute exposure to maternal hyperoxygenation (MH) leads to measurable increases in fetal cerebral oxygenation from baseline in fetuses with CHD. The study aims to determine whether MH could be used as a chronic in-utero treatment strategy to promote brain growth/maturation to birth and to improve postnatal neurodevelopmental outcomes, and identify the types of CHD most likely to benefit from chronic MH.

  • Condition or Disease:Congenital Heart Disease
  • Intervention/Treatment: Other: Oxygen gas
  • Phase: N/A
Detailed Description

This study determines the impact of administering oxygen to mother during the later part of pregnancy on cerebral oxygen delivery in fetuses who were identified with severe forms of Congenital Heart disease (CHD) including the following groups: - Group 1: Single ventricular (SV) lesions, including hypoplastic left heart syndrome (HLHS); pulmonary atresia with intact ventricular septum (PA/IVS); tricuspid atresia (TA); unbalanced AV septal defect (AVSD); double inlet ventricle (DILV); and severe form of Ebstein's anomaly (EA with pulmonary atresia) of the tricuspid valve; and - Group 2: Tetralogy of Fallot (TOF),including TOF-like double outlet right ventricle (DORV), pulmonary atresia with ventricular septal defect (PA/VSD) - Group 3: Bi-ventricular lesions with transposition of the great arteries (TGA), including DORV with TGA Children with severe CHD experience challenges in multiple developmental domains, impacting executive function, memory, language, and other aspects of cognitive and motor function. It is now well established that brain growth and development are adversely affected by CHD and it is increasingly clear that central nervous system changes that occur in the third trimester play a particularly important role in the pathogenesis of adverse neurodevelopmental outcomes. Supplemental maternal oxygen will used in the last trimester for a short period of time (acute MH) in pregnant mothers carrying babies with CHD to briefly increase fetal oxygen levels to those reached in the newborn with spontaneous breathing. This study will examine whether and to what degree acute MH will improve the cerebrovascular oxygenation. The rate and duration of MH (10 to 15L/min by mask for up to 30-45 minutes/test) is considered to be safe to the mother and her fetus. Both fetal echocardiography and fetal MRI will be used to determine the effects of acute MH on the fetal-placental circulation and will determine in fetuses with CHD whether acute exposure to MH leads to measurable increases in fetal cerebral oxygenation from baseline. Thus it could potentially become useful as a chronic in-utero treatment strategy to promote brain growth/maturation to birth and to improve postnatal neurodevelopmental outcomes.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 170 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Congenital Heart Disease (CHD): Hemodynamic Effects of Acute Maternal Hyperoxygenation in the Fetus
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: December 2022
  • Estimated Study Completion Date: December 2023
Arms and interventions
Arm Intervention/treatment
Experimental: Severe fetal congenital heart disease (CHD)
Mothers whose fetuses have a diagnosis of CHD will be exposed to 10-15 L/minute of oxygen while undergoing echocardiogaphy and MRI scanning
Other: Oxygen gas
Transient maternal oxygen administration during echocardiographic and MRI imaging
Outcome Measures
  • Primary Outcome Measures: 1. Characterize the hemodynamic effects of acute MH on fetuses with a) SV lesions and biventricular anomalies b) with TOF and c) with TGA. [ Time Frame: Outcome measure obtained during hyperoxygenation while undergoing echocardiography and MRI ]
    The affect MH has on the cerebral oxygenation from baseline for each type of CHD will be characterized using the MRI variables of cerebral oxygen delivery (cDO2) and cerebral oxygen consumption(cVO2) , which are calculated using fluximetry measurements (ml/min/m2) and the oxymetry of the ascending aorta and the superior vena cava
  • Secondary Outcome Measures: 1. Determine the pulmonary and placental vascular response to acute MH for each CHD [ Time Frame: Outcome measure obtained during hyperoxygenation while undergoing echocardiography and MRI ]
    The pulmonary and placental vascular response to acute MH for each CHD type will be measured using the placenta T2 star variable and the variables related to main pulmonary artery and branch pulmonary artery flow. Pulmonary vaso-reactivity to oxygen by echocardiography defined by a decrease the branch PA PI of ≥10%.
  • Other Outcome Measures: 1. Assess the relationship between fetal brain volumes and cerebral oxygen delivery [ Time Frame: Outcome measure obtained during hyperoxygenation while undergoing echocardiography and MRI ]
    The fetal brain volumetry (mL) and rate of cerebral oxygen delivery (cDO2 ml/min/m2) at the time of the baseline fetal MRI will be compared
  • 2. To compare the prenatal measurement of placenta and the growth in body and brain size at birth. [ Time Frame: Date of echocardiography/MRI to the date of the infant's birth, when the birth weight, height and head circumference data become available. ]
    The placental measurement by MRI will be correlated with head circumference and body weight at birth.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Pregnant mothers ≥18 years of age

- Written maternal informed consent

- Fetal diagnosis of one of the CHDs (1-3) as listed below and intention of active
treatment after birth:

1. Single ventricular (SV) lesions: hypoplastic left heart syndrome (HLHS);
pulmonary atresia with intact ventricular septum (PA/IVS); tricuspid atresia
(TA); unbalanced AV septal defect (AVSD); double inlet ventricle (DILV); and
severe form of Ebstein's anomaly (EA) of the tricuspid valve associated with
functional or anatomical right outflow obstruction. HLHS will include aortic
stenosis with mitral stenosis, aortic atresia with mitral stenosis or mitral
atresia. Pulmonary or aortic obstruction is defined as a condition with minimal
or absent antegrade flow across the respective valve. Severe forms of EA is
defined as lesion without anterograde pulmonary flow in the setting of severe
tricuspid regurgitation.

2. Bi-ventricular lesions with right ventricular outflow tract obstruction
(BV/RVOTO); tetralogy of Fallot (TOF), TOF-like double outlet right ventricle
(DORV), and pulmonary atresia with ventricular septal defect (PA/VSD).

3. Bi-ventricular lesions with transposed great arteries (TGA w/ VSD; TGA w/o VSD;
DORV with TGA)

Exclusion Criteria:

- Termination of pregnancy

- Unusual CHDs (e.g. EA with circular shunt, TOF with AVSD, and TOF with absent
pulmonary valve syndrome, TGA associated with moderate- severe outflow tract
obstruction

- Complex cardiac condition (e.g poor fetal cardiac function and/or fetal hydrops, fetal
arrhythmia such as frequent premature atrial beats, abnormal baseline heart rate ( 160 bpm) in the third trimester)

- Major non-cardiac lesions and major genetic abnormalities affecting brain size and
development

- Significant maternal co-morbidities that precludes a fetal MRI (e.g. significant
obesity, claustrophobia)

- Multiple pregnancy

Contacts and Locations
Contacts

Contact: Edger Jaeggi, MD, FRCP(C) (416) 813-7466 edgar.jaeggi@sickkids.ca

Contact: Mika Saito, MD 46-813-7500 mika.saito@sickkids.ca

Locations

Canada, Ontario
The Hospital for Sick Children
Toronto

Sponsors and Collaborators

The Hospital for Sick Children

Investigators

Principal Investigator: Edgar Jaeggi, MD, FRCP(C) The Hospital for Sick Children

More Information
  • Responsible Party: The Hospital for Sick Children
  • ClinicalTrials.gov Identifier: NCT03944837 History of Changes
  • Other Study ID Numbers: 1000062939
  • First Posted: May 10, 2019 Key Record Dates
  • Last Update Posted: August 12, 2020
  • Last Verified: August 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by The Hospital for Sick Children: MRI
    Acute maternal hyperoxygenation
    Echocardiography
  • Additional relevant MeSH terms: Heart Diseases Heart Defects, Congenital